A Phase 1, Open-Label, Dose Escalation Study of ANA773 Tosylate, an Oral Prodrug of a Toll-Like Receptor-7 Agonist, in Patients with Advanced Cancer (Anadys Protocol #ANA773-501)

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of ANA773 Tosylate, an Oral Prodrug of a Toll-Like Receptor-7 Agonist, in Patients with Advanced Cancer (Anadys Protocol #ANA773-501)

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2011

At a glance

  • Drugs RG 7795 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 May 2011 Results were reported in an Anadys media release and will be presented at the Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 26 May 2011 Status changed from not stated to completed.
    • 24 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top